Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In an attempt to overcome resistance to immune checkpoint inhibitors (ICI), an ever-increasing number of trials are exploring combination treatment approaches. Outcomes of a novel ICI doublet presented by Desai and colleagues are discussed along with emerging novel strategies and a view to future ongoing rational trial design maximising patient benefit.
Cancer services were seriously disrupted during the COVID-19 pandemic. Using publicly available data for England, we show that breast cancer diagnoses decreased substantially in the first year of the pandemic, but have recovered to at least pre-pandemic levels. Long term follow-up is needed to assess the impact on outcomes.